To learn more, visit Forward Looking Statements Moderna has been named a top biopharmaceutical employer by Science for the past seven years. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most-effective vaccines against the COVID-19 pandemic. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. In Latin America, Moderna has established bilateral and supranational supply agreements in 15 countries. In 2021, 807 million doses of Moderna's COVID-19 vaccine were shipped globally, with approximately 25% of those doses shipped to low- and middle-income markets.
Regulators have approved Moderna's COVID-19 vaccine in more than 70 markets, including Canada, Japan, the European Union, the UK, and Israel. In addition, Moderna announced an agreement with Gavi, the Vaccine Alliance, to supply up to 650 million doses of the Company's COVID-19 Vaccine across 20, covering the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries. The Company also has commercial agreements with distributors to supply the Company's COVID-19 vaccine in 45 countries, with Zuellig Pharma in the Asia Pacific, Medison Pharma in Central Eastern Europe and Israel, and Adium Pharma in Latin America. Moderna has a commercial presence in 11 countries worldwide (Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, Switzerland, UK, U.S.) and recently announced plans to increase its commercial footprint across ten additional markets in Asia-Pacific (Hong Kong, Malaysia, Singapore, Taiwan) and Europe (Belgium, Denmark, the Netherlands, Norway, Poland, Sweden) in 2022. These partnerships and the expansion of our global commercial footprint position Moderna to play an important role in providing healthcare security against COVID-19 and future vaccine-preventable diseases."
"A presence in Latin America is a key part of our global commercial strategy. "Our new partnership with Adium will help ensure broad access and delivery of our Moderna COVID-19 vaccine to people across Latin America," said Stéphane Bancel, Chief Executive Officer of Moderna.
0 kommentar(er)
